ANVISA approves new Covid-19 vaccine
ANVISA has approved the registration of the Covid-19 vaccine (recombinant) from Zalika Farmacêutica Ltda.
A monovalent immunizer with recombinant protein S antigen and saponin adjuvant, increasing antibody production.
ELS helps from drug development to registration in Brazil, Latin America and Europe.
ontact your local ELS consultant or via email info@elssolutions.pt
ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.
Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.
Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.
